Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican vs Tacrolimus after CNI Withdrawal in Renal Transplant
NCT01399242Phase 4Unknown
- Sponsor
- Hospital Universitário São José
- Start
- Aug 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Hospital Universitário São José. Primary endpoint: Calculated Glomerular Filtration Rate at 96 weeks. Status: unknown.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01399242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399242.